TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics Limited has disclosed a notice from Regal Funds Management Asia Pte Limited in compliance with the Australian Takeovers Panel Guidance Note 20 on Equity Derivatives. This disclosure involves long equity derivative positions related to Alterity’s securities, highlighting a significant stake held by the investment manager, which may impact the company’s market perception and investor relations.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. The company is listed on both the Australian Securities Exchange (ASX) and NASDAQ, indicating a broad market focus.
Average Trading Volume: 13,832,480
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
See more data about ATH stock on TipRanks’ Stock Analysis page.